Pharvaris Unveils Data Validating Deucrictibant's Efficacy Across HAE Treatment Spectrum
Event summary
- Pharvaris presented translational, nonclinical, and clinical data at the Bradykinin Symposium 2026, highlighting deucrictibant's mechanism of action and efficacy.
- Phase 3 RAPIDe-3 trial data showed deucrictibant IR capsule reduced median time to symptom relief to 1.20 hours in North America and 1.28 hours in Europe/RoW.
- Long-term Phase 2 CHAPTER-1 OLE study demonstrated a durable reduction in HAE attack rate from 2.18 to 0.12 attacks per month over 22.2 months.
- Cardiovascular safety analysis confirmed deucrictibant's favorable profile with no QT prolongation or serious CV adverse events observed.
The big picture
Pharvaris' data presentations reinforce the scientific validation of bradykinin B2 receptor antagonism as a therapeutic approach for HAE. The company's focus on oral administration differentiates it in a market dominated by injectable solutions, potentially setting a new standard of care. The long-term efficacy and safety data position deucrictibant as a strong candidate for regulatory approval and commercialization in the rare disease space.
What we're watching
- Regulatory Pathway
- Whether the comprehensive data package will accelerate deucrictibant's NDA and MAA approval timelines for HAE treatment.
- Commercial Strategy
- How Pharvaris positions deucrictibant against existing injectable therapies given its oral administration and efficacy claims.
- Pipeline Expansion
- The pace at which Pharvaris advances deucrictibant into other bradykinin-mediated conditions like AAE-C1INH.